STENTYS: Revenues for the 4th quarter of 2011
January 16 2012 - 1:08PM
Business Wire
STENTYS (Paris:STNT)(FR0010949404 – STNT), a medical
technology company commercializing the world's first and only
self-apposing stent to treat Acute Myocardial Infarction (AMI),
today reports its revenues for the 4th quarter and
full year to 31 December 2011.
- 2011 revenues, quarterly and
annual
In € thousands*
2010** 2011 Q1
n/a 251.4
Q2 n/a 347.6
Q3
87.5 371.0
Q4 145.9 463.0
FY
– 12 months 305.6 1,432.0
*unaudited
** the Company did not draw up quarterly results prior to its
IPO, so a comparison with the first half of 2010 cannot be made
Revenues for the 4th quarter of 2011 totalled €463.0k, an
increase of 25% over the 3rd quarter of 2011 and more than triple
the figure recorded over the 4th quarter of 2010. For its first
full year of activity, STENTYS recorded annual revenues of €1.4
million.
STENTYS continued to benefit from the gradual ramping up of
sales in the six new countries opened in 2011, which represented
almost half (47%) of 4th quarter sales. The Company’s self-apposing
stent is currently in its pre-marketing phase in 8 European
countries.
At 31 December 2011, STENTYS had a cash position of €14.7m,
reflecting efficient cost control throughout 2011.
- 2012, a year of many
developments
STENTYS expects numerous developments in 2012.
On the clinical side, the results of the international
APPOSITION III clinical trial on 1,000 patients 30 days after being
treated will be announced at the PCR congress in Paris in May. It
should be noted that the Company has already presented, back in
November 2011, outstanding interim results that further strengthen
the medical value of STENTYS’ self-apposing stents. The 12-month
interim results are expected by the end of the year. Moreover,
further studies will also be started, and in particular the
APPOSITION IV clinical trial that will prove the superiority of the
long-term apposition of STENTYS drug eluting stent compared to the
current market leader.
In 2012, the Company expects to receive FDA (Food and Drug
Administration) Investigational Device Exemption approval to carry
out the APPOSITION V clinical trial in the US, a necessary first
step to receive marketing authorisation in that country.
In terms of operations, STENTYS will continue its listing in the
largest hospitals of the 8 currently open European countries. This
market development will notably be carried out by organising
post-market studies or registries, such as the OPEN II study on
coronary lesions close to a bifurcation.
Gonzague Issenmann, Chief Executive Officer and co-founder of
STENTYS, concludes: “We are very pleased with the progress achieved
in 2011, in line with the business plan presented at the time of
our IPO, and we are perfectly ready for this new pivotal year that
should see FDA approval for the start of clinical trials in the
United States and solid growth in revenues.”
STENTYS will publish its 2011 annual results on 7 March 2012,
after market.
About STENTYS:
Based in Princeton, N.J., and Paris, Stentys has developed a new
generation of stents to treat acute myocardial infarction (AMI).
Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann,
Stentys received the CE mark for its flagship products in 2010. Its
self-apposing stents adapt to the anatomic changes of the arteries
in the post-infarction phase and thus prevent the malapposition
problems associated with conventional stents. Stentys has commenced
its marketing activities in several European countries.
More information on www.stentys.com.
STENTYS is listed on Compartment C of the NYSE
Euronext ParisISIN: FR0010949404 – Ticker: STNT